Hologic (HOLX) 10-Q 29 Jan 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Dec. 27, 2014	Jan. 23, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	27-Dec-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	HOLOGIC INC
Entity Central Index Key	859737
Current Fiscal Year End Date	-17
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		279,950,539

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Revenues:
Product	$546.60	$512.40
Service and other	106.2	100.1
Revenues	652.8	612.5
Costs of revenues:
Product	186.7	176.9
Amortization of intangible assets	73.9	76.7
Service and other	53.6	53.3
Gross Profit	338.6	305.6
Operating expenses:
Research and development	52	48.7
Selling and marketing	86	83.3
General and administrative	61.3	67.8
Amortization of intangible assets	27.8	26.2
Restructuring and divestiture charges	8	18.3
Operating expenses	235.1	244.3
Income from operations	103.5	61.3
Interest income	0.4	0.3
Interest expense	-52.5	-61.3
Debt extinguishment loss	-6.7	-2.9
Other (expense) income, net	-0.6	1.2
Income (loss) before income taxes	44.1	-1.4
Provision for income taxes	14.9	3.9
Net income (loss)	$29.20	($5.30)
Net income (loss) per common share:
Basic (in dollars per share)	$0.10	($0.02)
Diluted (in dollars per share)	$0.10	($0.02)
Weighted average number of shares outstanding:
Basic (in shares)	278,671	272,708
Diluted (in shares)	283,176	272,708

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Statement of Comprehensive Income [Abstract]
Net income (loss)	$29.20	($5.30)
Changes in foreign currency translation adjustment	-9	-1.2
Changes in unrealized holding gains and losses on available-for-sale securities	5.1	-1.2
Changes in pension plans, net of taxes of $0.2 in fiscal 2014	0.1	-0.6
Other comprehensive loss	-3.8	-3
Comprehensive income (loss)	$25.40	($8.30)

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Statement of Comprehensive Income [Abstract]
Changes in pension plans, tax	$0	$0.20

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$544	$736.10
Restricted cash	5.1	5.5
Accounts receivable, less reserves of $11.9 and $12.0, respectively	400.5	396
Inventories	310.3	330.6
Deferred income tax assets	39	39.4
Prepaid income taxes	0	22.4
Prepaid expenses and other current assets	37.7	35.8
Total current assets	1,336.60	1,565.80
Property, plant and equipment, net	458.2	461.9
Intangible assets, net	3,332.10	3,433.60
Goodwill	2,809.90	2,810.80
Other assets	141.3	142.6
Total assets	8,078.10	8,414.70
Current liabilities:
Current portion of long-term debt	139.4	114.5
Accounts payable	67	92.1
Accrued expenses	253	262.1
Deferred revenue	148.4	150.9
Total current liabilities	607.8	619.6
Long-term debt, net of current portion	3,815.40	4,153.20
Deferred income tax liabilities	1,345.70	1,375.40
Deferred service obligations – long-term	19.8	20.1
Other long-term liabilities	187	183.4
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 279,466 and 277,972 shares issued, respectively	2.8	2.8
Additional paid-in-capital	5,672.10	5,658.20
Accumulated deficit	-3,571.30	-3,600.60
Accumulated other comprehensive income (loss)	-1.2	2.6
Total stockholders’ equity	2,102.40	2,063
Total liabilities and stockholders’ equity	$8,078.10	$8,414.70

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, reserves	$11.90	$12
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	279,466,000	277,972,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
OPERATING ACTIVITIES
Net income (loss)	$29.20	($5.30)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	20.3	24.9
Amortization	101.7	102.9
Non-cash interest expense	16.7	19.7
Stock-based compensation expense	12.1	13.7
Excess tax benefit related to equity awards	-3	-3
Deferred income taxes	-30.5	-125.1
Asset impairment charges	0	3.1
Debt extinguishment loss	6.7	2.9
Loss on disposal of property and equipment	1.7	1.4
Other	1.2	-0.9
Changes in operating assets and liabilities:
Accounts receivable	-9.7	15.6
Inventories	18.7	-14.1
Prepaid income taxes	22.4	44.7
Prepaid expenses and other assets	-3	2.1
Accounts payable	-24.8	10.4
Accrued expenses and other liabilities	-5	53.7
Deferred revenue	-1.2	2.6
Net cash provided by operating activities	153.5	149.3
INVESTING ACTIVITIES
Net proceeds from sale of business	0	2.4
Purchase of property and equipment	-10.8	-8.4
Increase in equipment under customer usage agreements	-10.3	-8
Net (purchases) sales of insurance contracts	-6.4	13.8
Purchases of mutual funds	0	-29.7
Sales of mutual funds	6.4	15.9
Increase in other assets	-0.9	-0.4
Net cash used in investing activities	-22	-14.4
FINANCING ACTIVITIES
Repayment of long-term debt	-328.8	-521.3
Net proceeds from issuance of common stock pursuant to employee stock plans	15.2	12.9
Excess tax benefit related to equity awards	3	3
Payment of minimum tax withholdings on net share settlements of equity awards	-10.6	-9.1
Net cash used in financing activities	-321.2	-514.5
Effect of exchange rate changes on cash and cash equivalents	-2.4	-0.4
Net decrease in cash and cash equivalents	-192.1	-380
Cash and cash equivalents, beginning of period	736.1	822.5
Cash and cash equivalents, end of period	$544	$442.50

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Dec. 27, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended September 27, 2014 included in the Company’s Form 10-K filed with the SEC on November 20, 2014. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 27, 2014 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2015.
	Subsequent Events Consideration
	The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events recorded in the unaudited consolidated financial statements as of and for the three months ended December 27, 2014.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Dec. 27, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
	The Company has investments in publicly-traded companies and mutual funds, both of which are valued using quoted market prices, representing Level 1 assets. The Company has a payment obligation to the participants under its Nonqualified Deferred Compensation Plan (“DCP”). This liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1.
	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 27, 2014:
				Fair Value at Reporting Date Using
		Balance as of December 27, 2014		Quoted Prices in		Significant		Significant
				Active Market for		Other		Unobservable
				Identical Assets		Observable		Inputs (Level 3)
				(Level 1)		Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity securities	$	29.5	$	29.5	$	—	$	—
	Mutual funds	9.4		9.4		—		—
	Total	$	38.9	$	38.9	$	—	$	—
	Liabilities:
	Deferred compensation liabilities	$	37.1	$	37.1	$	—	$	—
	Total	$	37.1	$	37.1	$	—	$	—
	Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
	The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill.
	In the first quarter of fiscal 2014, the Company recorded a $3.1 million impairment charge to record certain of its buildings at fair value related to the Hitec-Imaging organic photoconductor manufacturing line shutdown (see Note 3). The Company believes this adjustment falls within Level 3 of the fair value hierarchy.
	The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $5.2 million at each of December 27, 2014 and September 27, 2014, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost, less any write-downs for other-than-temporary impairment charges. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to do so would be impractical. In the first quarter of fiscal 2014, the Company recorded an other-than-temporary impairment charge of $0.7 million related to one of its cost-method equity investments.
	Disclosure of Fair Value of Financial Instruments
	The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value.
	Amounts outstanding under the Company’s Credit Agreement of $1.72 billion aggregate principal as of December 27, 2014 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s Senior Notes had a fair value of approximately $1.04 billion as of December 27, 2014 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes and represents a Level 1 measurement. Refer to Note 4 for the carrying amounts of the various components of the Company’s debt.
	The estimated fair values of the Company’s Convertible Notes at December 27, 2014 were as follows:
	2010 Notes	$	566.9
	2012 Notes	555.6
	2013 Notes	408.3
		$	1,530.80

Restructuring_and_Divestiture_

Restructuring and Divestiture Charges	3 Months Ended
	Dec. 27, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Divestiture Charges	Restructuring and Divestiture Charges
	The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. In addition, it is continually assessing its management structure. As a result of these assessments, the Company has undertaken various restructuring actions, which are described below. The following table displays charges taken in fiscal 2015 and 2014 related to these actions and a rollforward of the accrued balances from September 27, 2014 to December 27, 2014:
		Consolidation of Diagnostics Operations			Fiscal 2015 Actions			Fiscal 2014 Actions			Other Operating Cost Reductions			Total
	Fiscal 2014 charges:
	Workforce reductions	$	2.9		$	—		$	29.5		$	9.8		$	42.2
	Non-cash impairment charge	—			—			—			3.1			$	3.1
	Facility closure costs	—			—			—			0.6			0.6
	Other	0.1			—			—			0.2			0.3
	Fiscal 2014 restructuring charges	$	3		$	—		$	29.5		$	13.7		$	46.2
	Divestiture net charges													5.5
	Fiscal 2014 restructuring and divestiture charges													$	51.7
	Fiscal 2015 charges:
	Workforce reductions	$	0.1		$	2.5		$	4.5		$	0.2		$	7.3
	Facility closure costs	0.4			—			0.2			0.1			0.7
	Fiscal 2015 restructuring and divestiture charges	$	0.5		$	2.5		$	4.7		$	0.3		$	8
		Consolidation of Diagnostics Operations			Fiscal 2015 Actions			Fiscal 2014 Actions			Other Operating Cost Reductions			Total
	Rollforward of Accrued Restructuring
	Balance as of September 27, 2014	$	3		$	—		$	12		$	1.9		$	16.9
	Fiscal 2015 restructuring charges	0.5			2.5			4.7			0.3			8
	Stock-based compensation	—			(0.1		)	—			—			(0.1		)
	Severance payments	(2.4		)	(0.4		)	(6.5		)	(0.7		)	(10.0		)
	Other payments	(0.4		)	—			(0.4		)	(0.2		)	(1.0		)
	Balance as of December 27, 2014	$	0.7		$	2		$	9.8		$	1.3		$	13.8
	Consolidation of Diagnostics Operations
	In connection with its acquisition of Gen-Probe Incorporated (“Gen-Probe”) in August 2012, the Company implemented restructuring actions to consolidate its Diagnostics operations, including streamlining product development initiatives, reducing overlapping functional areas in sales, marketing and general and administrative functions, and consolidating manufacturing resources, field services and support. As a result, the Company terminated certain employees from Gen-Probe and its legacy diagnostics business in research and development, sales, marketing, and general and administrative functions. The Company also decided to move its legacy molecular diagnostics operations from Madison, Wisconsin to Gen-Probe’s facilities in San Diego, California. This transfer was completed at the end of fiscal 2014 and, as a result, many of the employees in Madison were terminated. The Company recorded severance and benefit charges pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), beginning in fiscal 2012 and through fiscal 2015. The Company recorded $3.0 million for severance and benefits in fiscal 2014. The Company recorded $0.5 million for facility closure costs and severance and benefits in the first quarter of fiscal 2015, and $0.8 million for severance and benefits in the first quarter of fiscal 2014.
	Fiscal 2015 Actions
	In the first quarter of fiscal 2015, the Company continued to make executive management changes resulting in the termination of certain executives and employees on a worldwide basis. In addition, the Company continued to consolidate and close certain international offices. Severance and benefit charges under these actions have been recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 720), and ASC 420 depending on the circumstances, and the Company recorded severance and benefit charges of $2.5 million in the first quarter of fiscal 2015. Included in the charge is $0.1 million of stock-based compensation for the acceleration of certain equity awards pursuant to their original terms.
	Fiscal 2014 Actions
	During the first quarter of fiscal 2014, the Company implemented a cost reduction initiative comprised of reducing headcount and evaluating research projects and operating costs. In connection with this plan, the Company terminated certain employees on a worldwide basis. The Company recorded the severance and benefit charges pursuant to ASC 420 and ASC 712, depending on the circumstances. The Company recorded $6.3 million of severance and benefit charges in the first quarter of fiscal 2014, which included $0.4 million of stock-based compensation.
	On December 6, 2013, Stephen P. MacMillan was appointed as President, Chief Executive Officer and a director of the Company. The employment of John W. Cumming, the Company’s prior President and Chief Executive Officer, terminated upon Mr. MacMillan’s appointment. The Company provided separation benefits to Mr. Cumming pursuant to his employment letter dated July 18, 2013 resulting in a charge of $6.6 million in the first quarter of fiscal 2014, which included $4.4 million of stock-based compensation related to the acceleration of all of Mr. Cumming’s outstanding equity awards in accordance with the existing terms of Mr. Cumming’s stock-based payment arrangements.
	In the second, third, and fourth quarters of fiscal 2014, the Company continued to make executive management changes and implemented additional cost reduction initiatives resulting in the termination of certain executives and employees on a worldwide basis. In addition, in the fourth quarter of fiscal 2014 the Company decided to consolidate and close certain international offices. Severance and benefit charges under these actions have been recorded pursuant to ASC 420 and ASC 712 depending on the circumstances, and the Company recorded severance and benefit charges of $16.6 million in fiscal 2014. Included in the charge is $1.8 million of stock-based compensation for the modification of the terms of equity awards to certain employees. The Company recorded $4.5 million for severance and benefits and $0.2 million for facility closure costs in the first quarter of fiscal 2015 related to this action. Since a portion of the charges are pursuant to ASC 420, the Company expects to incur approximately $1.8 million of additional charges in the remainder of fiscal 2015 as the severance benefits are recorded ratably over the required service period. Charges related to lease obligations will be recorded upon either the cease-use date or execution of a termination contract.
	Other Operating Cost Reductions:
	Hitec-Imaging Organic Photoconductor Manufacturing Line Shut-down
	In the fourth quarter of fiscal 2013, in connection with the Company’s cost reduction initiatives, the Company decided to shut-down its Hitec-Imaging organic photoconductor manufacturing line located in Germany. This production line is included within the Breast Health segment. As a result, the Company terminated certain employees, primarily in manufacturing, in fiscal 2014. During the first quarter of fiscal 2014, the Company completed its negotiations with the local Works Council to determine severance benefits for the approximately 95 affected employees. The Company recorded severance and benefit charges pursuant to ASC 420 and estimates the total severance and related charges related to this action will be approximately $9.5 million. The Company began notifying the affected employees in the second quarter of fiscal 2014, and as such no charges were recorded in the first quarter of fiscal 2014. The Company recorded charges of $8.7 million in fiscal 2014 in connection with terminating these employees. In the first quarter of fiscal 2015, the Company recorded $0.3 million for severance and benefits and facility closure costs. The Company also recorded an impairment charge of $3.1 million in the first quarter of fiscal 2014 to record certain buildings at this location to their estimated fair value.
	Divestitures
	In the fourth quarter of fiscal 2014, the Company completed the sale of its MRI breast coils product line and recorded a loss on disposal of $5.3 million. The Company is providing certain transition services, including the manufacturing and sale of inventory to the buyer, over a six-month period through March 2015.

Borrowings_and_Credit_Arrangem

Borrowings and Credit Arrangements	3 Months Ended
	Dec. 27, 2014
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements
	The Company’s borrowings consisted of the following:
		December 27,		September 27,
		2014		2014
	Current debt obligations, net of debt discount:
	Term Loan A	$	124.5	$	99.6
	Term Loan B	14.9		14.9
	Total current debt obligations	139.4		114.5
	Long-term debt obligations, net of debt discount:
	Term Loan A	747.1		796.7
	Term Loan B	820		1,120.90
	Senior Notes	1,000.00		1,000.00
	Convertible Notes	1,248.30		1,235.60
	Total long-term debt obligations	3,815.40		4,153.20
	Total debt obligations	$	3,954.80	$	4,267.70
	Credit Agreement
	On December 24, 2014, the Company voluntarily pre-paid $300.0 million of its Term Loan B facility. Pursuant to ASC 470, Debt (ASC 470), the Company recorded a debt extinguishment loss of $6.7 million in the first quarter of fiscal 2015 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment.
	On October 31, 2013, the Company voluntarily pre-paid $100.0 million of its Term Loan B facility, which was reflected in current debt obligations as of September 28, 2013. Pursuant to ASC 470, the Company recorded a debt extinguishment loss of $2.9 million in the first quarter of fiscal 2014 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment.
	Borrowings outstanding under the Credit Agreement for the three months ended December 27, 2014 and December 28, 2013 had weighted-average interest rates of 2.77% and 3.06%, respectively. The interest rates on the outstanding Term Loan A and Term Loan B borrowings at December 27, 2014 were 2.16% and 3.25%, respectively. Interest expense under the Credit Agreement totaled $17.6 million and $20.4 million for the three months ended December 27, 2014 and December 28, 2013, respectively, which includes non-cash interest expense of $3.1 million and $3.3 million related to the amortization of the deferred issuance costs and accretion of the debt discount, respectively.
	The credit facilities contain two financial ratio covenants measured as of the last day of each fiscal quarter: a total net leverage ratio and an interest coverage ratio. As of December 27, 2014, the Company was in compliance with these covenants.
	Senior Notes
	The Company’s 6.25% senior notes due 2020 (the “Senior Notes”) mature on August 1, 2020 and bear interest at the rate of 6.25% per year, payable semi-annually on February 1 and August 1 of each year, commencing on February 1, 2013. The Company recorded interest expense of $16.0 million in the three month periods ended December 27, 2014 and December 28, 2013, which includes non-cash interest expense of $0.4 million in the three month periods ended December 27, 2014 and December 28, 2013 related to the amortization of the deferred issuance costs.
	Convertible Notes
	Interest expense under the Convertible Notes is as follows:
		Three Months Ended
		December 27,		December 28,
		2014		2013
	Amortization of debt discount	$	8.8	$	11.5
	Amortization of deferred financing costs	0.4		0.7
	Principal accretion	3.9		3.8
	Non-cash interest expense	13.1		16
	2.00% accrued interest (cash)	4.8		8.1
		$	17.9	$	24.1

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 27, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Litigation and Related Matters
	On June 9, 2010, Smith & Nephew, Inc. ("Smith & Nephew") filed suit against Interlace Medical, Inc. ("Interlace"), which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringed U.S. patent 7,226,459. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. Both complaints sought permanent injunctive relief and unspecified damages. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million. A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court also rejected the jury’s damage award and ordered the parties to identify a mechanism for resolving the damages issue. On September 12, 2013, a status conference was held, and the Court invited the parties to submit briefs on the relevance of recent activity in the re-examinations at the USPTO. A hearing on this topic was held on October 29, 2013, and the parties are awaiting the Court’s ruling. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. On January 14, 2014, the USPTO issued a final decision that the claims of the ‘459 patent asserted as part of the litigation are not patentable. On February 13, 2014, Smith & Nephew appealed this decision to the U.S. Patent Trial and Appeal Board. The re-examination of the ‘359 patent is on-going. It is expected that patentability decisions made by the USPTO for both patents will proceed to appeal. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
	On March 6, 2012, Enzo Life Sciences, Inc. (“Enzo”) filed suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. The Company was formally served with the complaint on July 3, 2012, and a trial is tentatively scheduled for the fall of 2015. In January 2012, Enzo filed suit against Gen-Probe in the United States District Court for the District of Delaware. The Gen-Probe complaint alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented hybridization protection assay technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. patent 6,992,180. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, MilliPROBE, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages. Enzo has asserted the ‘180 patent claims against six other companies. The defendant companies are jointly arguing issues related to claim construction, and the trials are tentatively scheduled to begin in the fall of 2015. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
	On October 29, 2013, the Interlace stockholder representatives filed a complaint in the Delaware Court of Chancery alleging breach of contract for issues related to the payment of contingent consideration under the Interlace acquisition agreement, and sought $14.7 million in additional payments. On October 20, 2014, a trial was held in Delaware. The parties executed a settlement agreement in January 2015 for an amount less than that sought. The Company had accrued certain amounts to settle this litigation as of September 27, 2014 and the effect of this settlement was not material to the Company's financial statements.
	The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those described above there are no other proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Marketable_Securities

Marketable Securities	3 Months Ended
	Dec. 27, 2014
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities
	The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale:
	Period Ended:	Cost		Gross Unrealized		Gross Unrealized			Fair Value
				Gains		Losses
	27-Dec-14	$	15.5	$	19.7	$	(5.7	)	$	29.5
	27-Sep-14	$	15.5	$	10.2	$	(1.3	)	$	24.4

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	3 Months Ended
	Dec. 27, 2014
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share
	A reconciliation of basic and diluted share amounts is as follows:
		Three Months Ended
		December 27,	December 28,
		2014	2013
	Basic weighted average common shares outstanding	278,671	272,708
	Weighted average common stock equivalents from assumed exercise of stock options and stock units	2,464	—
	Incremental shares from assumed conversion of the Convertible Notes premium	2,041	—
	Diluted weighted average common shares outstanding	283,176	272,708
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	3,782	7,199
	Stock units	140	950
	The Company has outstanding Convertible Notes, and the principal balance and any conversion premium may be satisfied, at the Company’s option, by issuing shares of common stock, cash or a combination of shares and cash. The Company's policy is that it will settle the principal balance of the Convertible Notes in cash. As such, the Company applies the treasury stock method to these securities and the dilution related to the conversion premium of the 2010 Notes is included in the calculation of diluted weighted-average shares outstanding for the three months ended December 27, 2014 as the average stock price during the quarter was greater than the conversion price of the 2010 Notes.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Cost of revenues	$	2		$	1.5
	Research and development	1.9			1.9
	Selling and marketing	2			1.7
	General and administrative	6.1			3.8
	Restructuring and divestiture	0.1			4.8
		$	12.1		$	13.7
	The Company granted approximately 1.0 million and 2.0 million stock options during the three months ended December 27, 2014 and December 28, 2013, respectively, with weighted-average exercise prices of $26.12 and $21.82, respectively. There were 9.2 million options outstanding at December 27, 2014 with a weighted-average exercise price of $21.34.
	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Risk-free interest rate	1.7		%	1.2		%
	Expected volatility	38.6		%	41.4		%
	Expected life (in years)	5.3			4.4
	Dividend yield	—			—
	Weighted average fair value of options granted	$	9.44		$	7.64
	The Company granted approximately 1.3 million and 2.0 million restricted stock units (RSUs) during the three months ended December 27, 2014 and December 28, 2013, respectively, with weighted-average grant date fair values of $26.17 and $21.51, respectively. As of December 27, 2014, there were 4.0 million unvested RSUs outstanding with a weighted-average grant date fair value of $22.95. In addition, consistent with the Company's annual grant in fiscal 2014, the Company granted approximately 0.3 million performance stock units (PSUs) in the first quarter of fiscal 2015 to members of its senior management team, which have a weighted-average grant date fair value of $26.21. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company is recognizing compensation expense ratably over the required service period based on its estimate that it is probable the targeted number of shares will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made.
	At December 27, 2014, there was $29.4 million and $90.5 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs and PSUs), respectively, to be recognized over a weighted-average period of 3.7 years and 3.0 years, respectively.

Other_Balance_Sheet_Informatio

Other Balance Sheet Information	3 Months Ended
	Dec. 27, 2014
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information
		December 27,			September 27,
		2014			2014
	Inventories
	Raw materials	$	112		$	115.6
	Work-in-process	53			57.1
	Finished goods	145.3			157.9
		$	310.3		$	330.6
	Property, plant and equipment
	Equipment and software	$	345.4		$	342.5
	Equipment under customer usage agreements	288.6			285.2
	Building and improvements	179.5			176.9
	Leasehold improvements	59.7			63.2
	Land	51.5			51.6
	Furniture and fixtures	16.4			16.3
		941.1			935.7
	Less – accumulated depreciation and amortization	(482.9		)	(473.8		)
		$	458.2		$	461.9

Business_Segments_and_Geograph

Business Segments and Geographic Information	3 Months Ended
	Dec. 27, 2014
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information
	The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring and divestiture charges and other one-time or unusual items.
	Identifiable assets for the four principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three months ended December 27, 2014 and December 28, 2013. Segment information is as follows:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Total revenues:
	Diagnostics	$	304.1		$	285.7
	Breast Health	242			226.5
	GYN Surgical	84.4			78.9
	Skeletal Health	22.3			21.4
		$	652.8		$	612.5
	Operating income:
	Diagnostics	$	28.2		$	4.8
	Breast Health	60.6			43.8
	GYN Surgical	13.1			11.1
	Skeletal Health	1.6			1.6
		$	103.5		$	61.3
	Depreciation and amortization:
	Diagnostics	$	88.6		$	92.2
	Breast Health	7.6			9.4
	GYN Surgical	25.6			26
	Skeletal Health	0.2			0.2
		$	122		$	127.8
	Capital expenditures:
	Diagnostics	$	14.8		$	10.3
	Breast Health	2.6			1.8
	GYN Surgical	2			1.8
	Skeletal Health	0.2			0.1
	Corporate	1.5			2.4
		$	21.1		$	16.4
		December 27,			September 27,
		2014			2014
	Identifiable assets:
	Diagnostics	$	4,294.50		$	4,383.50
	Breast Health	847.3			859.8
	GYN Surgical	1,726.80			1,748.20
	Skeletal Health	25.1			26.1
	Corporate	1,184.40			1,397.10
		$	8,078.10		$	8,414.70
	The Company had no customers with balances greater than 10% of accounts receivable as of December 27, 2014 or September 27, 2014, or any customer that represented greater than 10% of consolidated revenues during the three months ended December 27, 2014 and December 28, 2013.
	The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
	Revenues by geography as a percentage of total revenues were as follows:
		Three Months Ended
		December 27,		December 28,
		2014		2013
	United States	74	%	75	%
	Europe	13	%	14	%
	Asia-Pacific	9	%	7	%
	All others	4	%	4	%
		100	%	100	%

Income_Taxes

Income Taxes	3 Months Ended
	Dec. 27, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.
	The Company’s effective tax rate for the three month period ended December 27, 2014 was 33.8% compared to a provision of 277.1% on a pre-tax loss for the corresponding period in the prior year. For the current three month period, the effective tax rate differed from the statutory rate primarily due to the domestic production activities deduction. For the three months ended December 28, 2013, the tax rate was higher than the statutory rate primarily due to unbenefited foreign losses.

Intangible_Assets

Intangible Assets	3 Months Ended
	Dec. 27, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets
	Intangible assets consisted of the following:
	Description	As of December 27, 2014				As of September 27, 2014
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Value				Value
	Developed technology	$	3,965.20	$	1,464.20	$	3,951.10	$	1,390.50
	In-process research and development	3.7		—		17.9		—
	Customer relationships and contracts	1,102.30		405.7		1,102.40		384.7
	Trade names	236.4		111.8		236.5		105.3
	Patents	14.6		9		14.5		8.9
	Business licenses	2.6		2		2.6		2
		$	5,324.80	$	1,992.70	$	5,325.00	$	1,891.40
	During the first quarter of fiscal 2015, the Company received regulatory approval for one of its in-process research and development projects acquired in the Gen-Probe acquisition and reclassified this asset of $14.2 million to developed technology.
	The estimated remaining amortization expense as of December 27, 2014 for each of the five succeeding fiscal years is as follows:
	Remainder of Fiscal 2015	$	302.6
	Fiscal 2016	$	375.9
	Fiscal 2017	$	366.8
	Fiscal 2018	$	356.3
	Fiscal 2019	$	344.4

Product_Warranties

Product Warranties	3 Months Ended
	Dec. 27, 2014
Guarantees [Abstract]
Product Warranties	Product Warranties
	Product warranty activity was as follows:
		Balance at		Provisions		Settlements/			Balance at
		Beginning of				Adjustments			End of Period
		Period
	Three Months Ended:
	27-Dec-14	$	6.3	$	1.5	$	(1.8	)	$	6
	28-Dec-13	$	9.3	$	2	$	(2.4	)	$	8.9

New_Accounting_Pronouncements

New Accounting Pronouncements	3 Months Ended
	Dec. 27, 2014
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and earlier application is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition , and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.  ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016, which is fiscal 2018 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU 2013-11 did not have a material impact on the Company's consolidated financial position or results of operations.
	In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. ASU 2013-05 addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The adoption of ASU 2013-05 did not have a material impact on the Company's consolidated financial position or results of operations.

Supplemental_Guarantor_Condens

Supplemental Guarantor Condensed Consolidating Financials	3 Months Ended
	Dec. 27, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Supplemental Guarantor Condensed Consolidating Financials	Supplemental Guarantor Condensed Consolidating Financials
	The Company’s Senior Notes are fully and unconditionally and jointly and severally guaranteed by Hologic, Inc. (“Parent/Issuer”) and certain of its domestic subsidiaries, which are 100% owned by Hologic, Inc. The following represents the supplemental condensed financial information of Hologic, Inc. and its guarantor and non-guarantor subsidiaries, as of December 27, 2014 and September 27, 2014 and for the three months ended December 27, 2014 and December 28, 2013, as applicable.
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended December 27, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	131.6		$	425.8		$	120		$	(130.8	)	$	546.6
	Service and other	91			15.6			12.1			(12.5		)	106.2
		222.6			441.4			132.1			(143.3		)	652.8
	Costs of revenues:
	Product	58.3			170.9			88.3			(130.8		)	186.7
	Amortization of intangible assets	1.6			72.2			0.1			—			73.9
	Service and other	35.2			16.1			14.8			(12.5		)	53.6
	Gross Profit	127.5			182.2			28.9			—			338.6
	Operating expenses:
	Research and development	8.4			42			1.6			—			52
	Selling and marketing	24.4			40.5			21.1			—			86
	General and administrative	17.4			35.2			8.7			—			61.3
	Amortization of intangible assets	0.6			26.2			1			—			27.8
	Restructuring and divestiture charges	1.8			0.5			5.7			—			8
		52.6			144.4			38.1			—			235.1
	Income (loss) from operations	74.9			37.8			(9.2		)	—			103.5
	Interest income	(0.7		)	1.1			0.2			(0.2		)	0.4
	Interest expense	(51.8		)	(0.3		)	(0.6		)	0.2			(52.5		)
	Debt extinguishment loss	(6.7		)	—			—			—			(6.7		)
	Other (expense) income, net	50.7			(51.3		)	0.1			(0.1		)	(0.6		)
	Income (loss) before income taxes	66.4			(12.7		)	(9.5		)	(0.1		)	44.1
	Provision for income taxes	1.4			12.3			1.2			—			14.9
	Equity in earnings (losses) of subsidiaries	(35.8		)	2			—			33.8			—
	Net income (loss)	$	29.2		$	(23.0	)	$	(10.7	)	$	33.7		$	29.2
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended December 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	105.5		$	381.5		$	126.4		$	(101.0	)	$	512.4
	Service and other	85.9			15.9			11.8			(13.5		)	100.1
		191.4			397.4			138.2			(114.5		)	612.5
	Costs of revenues:
	Product	52.9			138.8			86.3			(101.1		)	176.9
	Amortization of intangible assets	1.4			74.1			1.2			—			76.7
	Service and other	42.3			7.6			16.8			(13.4		)	53.3
	Gross profit	94.8			176.9			33.9			—			305.6
	Operating expenses:
	Research and development	7.5			38.9			2.3			—			48.7
	Selling and marketing	17.9			42.8			22.6			—			83.3
	General and administrative	14.7			41.5			11.6			—			67.8
	Amortization of intangible assets	0.8			24.1			1.3			—			26.2
	Restructuring and divestiture charges	5			9.7			3.6			—			18.3
		45.9			157			41.4			—			244.3
	Income from operations	48.9			19.9			(7.5		)	—			61.3
	Interest income	0.1			0.3			0.1			(0.2		)	0.3
	Interest expense	(60.7		)	(0.3		)	(0.5		)	0.2			(61.3		)
	Debt extinguishment loss	(2.9		)	—			—			—			(2.9		)
	Other (expense) income, net	9.6			(9.3		)	0.9			—			1.2
	(Loss) income before income taxes	(5.0		)	10.6			(7.0		)	—			(1.4		)
	Provision (benefit) for income taxes	(0.1		)	1.6			2.4			—			3.9
	Equity in earnings (losses) of subsidiaries	(0.4		)	10.1			—			(9.7		)	—
	Net income (loss)	$	(5.3	)	$	19.1		$	(9.4	)	$	(9.7	)	$	(5.3	)
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
	For the Three Months Ended December 27, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
Net income (loss)	$	29.2		$	(23.0	)	$	(10.7	)	$	33.7		$	29.2
Changes in foreign currency translation adjustment	—			(0.3		)	(8.7		)	—			(9.0		)
Changes in unrealized holding gain on available-for-sale securities	—			5.1			—			—			5.1
Changes in pension plans, net of taxes	—			—			0.1			—			0.1
Comprehensive income (loss)	$	29.2		$	(18.2	)	$	(19.3	)	$	33.7		$	25.4
For the Three Months Ended December 28, 2013
	Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
				Subsidiaries			Subsidiaries
Net income (loss)	$	(5.3	)	$	19.1		$	(9.4	)	$	(9.7	)	$	(5.3	)
Changes in foreign currency translation adjustment	—			0.1			(1.3		)	—			(1.2		)
Changes in unrealized holding loss on available-for-sale securities	—			(1.2		)	—			—			(1.2		)
Changes in pension plans, net of taxes	—			—			(0.6		)	—			(0.6		)
Comprehensive income (loss)	$	(5.3	)	$	18		$	(11.3	)	$	(9.7	)	$	(8.3	)
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
December 27, 2014
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents	$	150.6		$	249.4		$	144		$	—		$	544
Restricted cash	—			—			5.1			—			5.1
Accounts receivable, net	116.2			198.2			86.1			—			400.5
Inventories	88			174.6			47.7			—			310.3
Deferred income tax assets	26.3			11.7			1			—			39
Prepaid income taxes	—			3.1			—			(3.1		)	—
Prepaid expenses and other current assets	18.5			10			9.2			—			37.7
Intercompany receivables	—			2,787.90			19			(2,806.9		)	—
Total current assets	399.6			3,434.90			312.1			(2,810.0		)	1,336.60
Property, plant and equipment, net	27.8			337.7			92.7			—			458.2
Intangible assets, net	23.6			3,279.00			40.1			(10.6		)	3,332.10
Goodwill	327.8			2,390.80			91.3			—			2,809.90
Other assets	82.7			57.3			1.3			—			141.3
Long term intercompany receivables	—			—			13			(13.0		)	—
Investment in subsidiaries	8,490.00			216.6			—			(8,706.6		)	—
Total assets	$	9,351.50		$	9,716.30		$	550.5		$	(11,540.2	)	$	8,078.10
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	139.4		$	—		$	—		$	—		$	139.4
Accounts payable	26.9			32.7			7.4			—			67
Accrued expenses	156.3			48.4			51.4			(3.1		)	253
Deferred revenue	111			8.3			29.1			—			148.4
Intercompany payables	2,763.90			—			43.2			(2,807.1		)	—
Total current liabilities	3,197.50			89.4			131.1			(2,810.2		)	607.8
Long-term debt, net of current portion	3,815.40			—			—			—			3,815.40
Deferred income tax liabilities	97.3			1,244.40			4			—			1,345.70
Deferred service obligations – long-term	8.6			3.9			7.3			—			19.8
Long-term intercompany payables	13			—			—			(13.0		)	—
Other long-term liabilities	117.3			33			36.7			—			187
Total stockholders’ equity	2,102.40			8,345.60			371.4			(8,717.0		)	2,102.40
Total liabilities and stockholders’ equity	$	9,351.50		$	9,716.30		$	550.5		$	(11,540.2	)	$	8,078.10
SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
September 27, 2014
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
ASSETS
Current assets:
Cash and cash equivalents	$	288.1		$	287.8		$	160.2		$	—		$	736.1
Restricted cash	—			—			5.5			—			5.5
Accounts receivable, net	128.4			182.5			85.1			—			396
Inventories	88.6			190.1			51.9			—			330.6
Deferred income tax assets	26.2			12.1			1.1			—			39.4
Prepaid income taxes	20.3			3.2			—			(1.1		)	22.4
Prepaid expenses and other current assets	16.2			11			8.6			—			35.8
Intercompany receivables	—			2,702.10			18.1			(2,720.2		)	—
Total current assets	567.8			3,388.80			330.5			(2,721.3		)	1,565.80
Property, plant and equipment, net	29.7			337.1			95.1			—			461.9
Intangible assets, net	25.1			3,377.30			41.9			(10.7		)	3,433.60
Goodwill	282.4			2,390.90			137.5			—			2,810.80
Other assets	88.4			52.7			1.5			—			142.6
Long term intercompany receivables	—			—			13			(13.0		)	—
Investments in subsidiaries	8,526.00			221.7			—			(8,747.7		)	—
Total assets	$	9,519.40		$	9,768.50		$	619.5		$	(11,492.7	)	$	8,414.70
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	114.5		$	—		$	—		$	—		$	114.5
Accounts payable	34.8			46.1			11.2			—			92.1
Accrued expenses	139.4			69.5			54.3			(1.1		)	262.1
Deferred revenue	113.5			7.4			30			—			150.9
Intercompany payables	2,676.20			—			44.2			(2,720.4		)	—
Total current liabilities	3,078.40			123			139.7			(2,721.5		)	619.6
Long-term debt, net of current portion	4,153.20			—			—			—			4,153.20
Deferred income tax liabilities	90.9			1,279.10			5.4			—			1,375.40
Deferred service obligations – long-term	8.3			3.6			8.2			—			20.1
Long-term intercompany payables	13			—			—			(13.0		)	—
Other long-term liabilities	112.6			34.3			36.5			—			183.4
Total stockholders’ equity	2,063.00			8,328.50			429.7			(8,758.2		)	2,063.00
Total liabilities and stockholders’ equity	$	9,519.40		$	9,768.50		$	619.5		$	(11,492.7	)	$	8,414.70
CONSOLIDATING STATEMENT OF CASH FLOWS
For the Three Months Ended December 27, 2014
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	$	186.9		$	(25.9	)	$	(7.5	)	$	—		$	153.5
INVESTING ACTIVITIES
Purchase of property and equipment	(2.4		)	(5.6		)	(2.8		)	—			(10.8		)
Increase in equipment under customer usage agreements	—			(6.5		)	(3.8		)	—			(10.3		)
Net purchases of insurance contracts	(6.4		)	—			—			—			(6.4		)
Sales of mutual funds	6.4			—			—			—			6.4
Increase in other assets	(0.8		)	(0.1		)	—			—			(0.9		)
Net cash used in investing activities	(3.2		)	(12.2		)	(6.6		)	—			(22.0		)
FINANCING ACTIVITIES
Repayment of long-term debt	(328.8		)	—			—			—			(328.8		)
Net proceeds from issuance of common stock pursuant to employee stock plans	15.2			—			—			—			15.2
Excess tax benefit related to equity awards	3			—			—			—			3
Payment of minimum tax withholdings on net share settlement of equity awards	(10.6		)	—			—			—			(10.6		)
Net cash used in financing activities	(321.2		)	—			—			—			(321.2		)
Effect of exchange rate changes on cash and cash equivalents	—			(0.3		)	(2.1		)	—			(2.4		)
Net decrease in cash and cash equivalents	(137.5		)	(38.4		)	(16.2		)	—			(192.1		)
Cash and cash equivalents, beginning of period	288.1			287.8			160.2			—			736.1
Cash and cash equivalents, end of period	$	150.6		$	249.4		$	144		$	—		$	544
CONSOLIDATING STATEMENT OF CASH FLOWS
For the Three Months Ended December 28, 2013
	Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
	Issuer			Subsidiaries			Subsidiaries
OPERATING ACTIVITIES
Net cash provided by operating activities	$	301.6		$	(142.0	)	$	(10.3	)	$	—		$	149.3
INVESTING ACTIVITIES
Net proceeds from sale of business	—			—			2.4			—			2.4
Purchase of property and equipment	(2.9		)	(3.2		)	(2.3		)	—			(8.4		)
Increase in equipment under customer usage agreements	(0.4		)	(4.3		)	(3.3		)	—			(8.0		)
Net sales of insurance contracts	13.8			—			—			—			13.8
Purchases of mutual funds	(29.7		)	—			—			—			(29.7		)
Sales of mutual funds	15.9			—			—			—			15.9
(Increase) decrease in other assets	0.1			(1.0		)	0.5			—			(0.4		)
Net cash provided by (used in) investing activities	(3.2		)	(8.5		)	(2.7		)	—			(14.4		)
FINANCING ACTIVITIES
Repayment of long-term debt	(521.3		)	—			—			—			(521.3		)
Net proceeds from issuance of common stock pursuant to employee stock plans	12.9			—			—			—			12.9
Excess tax benefit related to equity awards	3			—			—			—			3
Payment of minimum tax withholdings on net share settlements of equity awards	(9.1		)	—			—			—			(9.1		)
Net cash used in financing activities	(514.5		)	—			—			—			(514.5		)
Effect of exchange rate changes on cash and cash equivalents	—			0.1			(0.5		)	—			(0.4		)
Net decrease in cash and cash equivalents	(216.1		)	(150.4		)	(13.5		)	—			(380.0		)
Cash and cash equivalents, beginning of period	321.5			387.4			113.5			—			822.5
Cash and cash equivalents, end of period	$	105.4		$	237		$	100		$	—		$	442.5

New_Accounting_Pronouncements_

New Accounting Pronouncements (Policies)	3 Months Ended
	Dec. 27, 2014
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and earlier application is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's consolidated financial statements or disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 660), which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition , and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.  ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2016, which is fiscal 2018 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exist. ASU 2013-11 amends the presentation requirements of ASC 740 and requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. To the extent the tax benefit is not available at the reporting date under the governing tax law or if the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented as a liability and not combined with deferred tax assets. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The amendments are to be applied to all unrecognized tax benefits that exist as of the effective date and may be applied retrospectively to each prior reporting period presented. The adoption of ASU 2013-11 did not have a material impact on the Company's consolidated financial position or results of operations.
	In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. ASU 2013-05 addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income. The ASU is effective for annual periods, and interim periods within those years, beginning after December 15, 2013, which is fiscal 2015 for the Company. The adoption of ASU 2013-05 did not have a material impact on the Company's consolidated financial position or results of operations.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 27, 2014
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 27, 2014:
				Fair Value at Reporting Date Using
		Balance as of December 27, 2014		Quoted Prices in		Significant		Significant
				Active Market for		Other		Unobservable
				Identical Assets		Observable		Inputs (Level 3)
				(Level 1)		Inputs (Level 2)
	Assets:
	Marketable securities:
	Equity securities	$	29.5	$	29.5	$	—	$	—
	Mutual funds	9.4		9.4		—		—
	Total	$	38.9	$	38.9	$	—	$	—
	Liabilities:
	Deferred compensation liabilities	$	37.1	$	37.1	$	—	$	—
	Total	$	37.1	$	37.1	$	—	$	—
Estimated Fair Values of Convertible Notes	The estimated fair values of the Company’s Convertible Notes at December 27, 2014 were as follows:
	2010 Notes	$	566.9
	2012 Notes	555.6
	2013 Notes	408.3
		$	1,530.80

Restructuring_and_Divestiture_1

Restructuring and Divestiture Charges (Tables)	3 Months Ended
	Dec. 27, 2014
Restructuring and Related Activities [Abstract]
Charges Taken Related to Restructuring Actions	The following table displays charges taken in fiscal 2015 and 2014 related to these actions and a rollforward of the accrued balances from September 27, 2014 to December 27, 2014:
		Consolidation of Diagnostics Operations			Fiscal 2015 Actions			Fiscal 2014 Actions			Other Operating Cost Reductions			Total
	Fiscal 2014 charges:
	Workforce reductions	$	2.9		$	—		$	29.5		$	9.8		$	42.2
	Non-cash impairment charge	—			—			—			3.1			$	3.1
	Facility closure costs	—			—			—			0.6			0.6
	Other	0.1			—			—			0.2			0.3
	Fiscal 2014 restructuring charges	$	3		$	—		$	29.5		$	13.7		$	46.2
	Divestiture net charges													5.5
	Fiscal 2014 restructuring and divestiture charges													$	51.7
	Fiscal 2015 charges:
	Workforce reductions	$	0.1		$	2.5		$	4.5		$	0.2		$	7.3
	Facility closure costs	0.4			—			0.2			0.1			0.7
	Fiscal 2015 restructuring and divestiture charges	$	0.5		$	2.5		$	4.7		$	0.3		$	8
Charges Taken Related to Accrued Restructuring Actions
		Consolidation of Diagnostics Operations			Fiscal 2015 Actions			Fiscal 2014 Actions			Other Operating Cost Reductions			Total
	Rollforward of Accrued Restructuring
	Balance as of September 27, 2014	$	3		$	—		$	12		$	1.9		$	16.9
	Fiscal 2015 restructuring charges	0.5			2.5			4.7			0.3			8
	Stock-based compensation	—			(0.1		)	—			—			(0.1		)
	Severance payments	(2.4		)	(0.4		)	(6.5		)	(0.7		)	(10.0		)
	Other payments	(0.4		)	—			(0.4		)	(0.2		)	(1.0		)
	Balance as of December 27, 2014	$	0.7		$	2		$	9.8		$	1.3		$	13.8

Borrowings_and_Credit_Arrangem1

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Dec. 27, 2014
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following:
		December 27,		September 27,
		2014		2014
	Current debt obligations, net of debt discount:
	Term Loan A	$	124.5	$	99.6
	Term Loan B	14.9		14.9
	Total current debt obligations	139.4		114.5
	Long-term debt obligations, net of debt discount:
	Term Loan A	747.1		796.7
	Term Loan B	820		1,120.90
	Senior Notes	1,000.00		1,000.00
	Convertible Notes	1,248.30		1,235.60
	Total long-term debt obligations	3,815.40		4,153.20
	Total debt obligations	$	3,954.80	$	4,267.70
Interest Expense under Convertible Notes	Interest expense under the Convertible Notes is as follows:
		Three Months Ended
		December 27,		December 28,
		2014		2013
	Amortization of debt discount	$	8.8	$	11.5
	Amortization of deferred financing costs	0.4		0.7
	Principal accretion	3.9		3.8
	Non-cash interest expense	13.1		16
	2.00% accrued interest (cash)	4.8		8.1
		$	17.9	$	24.1

Marketable_Securities_Tables

Marketable Securities (Tables)	3 Months Ended
	Dec. 27, 2014
Investments, Debt and Equity Securities [Abstract]
Reconciles Cost Basis to Fair Market Value of Company's Equity Security	The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale:
	Period Ended:	Cost		Gross Unrealized		Gross Unrealized			Fair Value
				Gains		Losses
	27-Dec-14	$	15.5	$	19.7	$	(5.7	)	$	29.5
	27-Sep-14	$	15.5	$	10.2	$	(1.3	)	$	24.4

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Dec. 27, 2014
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows:
		Three Months Ended
		December 27,	December 28,
		2014	2013
	Basic weighted average common shares outstanding	278,671	272,708
	Weighted average common stock equivalents from assumed exercise of stock options and stock units	2,464	—
	Incremental shares from assumed conversion of the Convertible Notes premium	2,041	—
	Diluted weighted average common shares outstanding	283,176	272,708
	Weighted-average anti-dilutive shares related to:
	Outstanding stock options	3,782	7,199
	Stock units	140	950

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Cost of revenues	$	2		$	1.5
	Research and development	1.9			1.9
	Selling and marketing	2			1.7
	General and administrative	6.1			3.8
	Restructuring and divestiture	0.1			4.8
		$	12.1		$	13.7
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Risk-free interest rate	1.7		%	1.2		%
	Expected volatility	38.6		%	41.4		%
	Expected life (in years)	5.3			4.4
	Dividend yield	—			—
	Weighted average fair value of options granted	$	9.44		$	7.64

Other_Balance_Sheet_Informatio1

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 27, 2014
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories
		December 27,			September 27,
		2014			2014
	Inventories
	Raw materials	$	112		$	115.6
	Work-in-process	53			57.1
	Finished goods	145.3			157.9
		$	310.3		$	330.6
Other Balance Sheet Information of Property, Plant and Equipment
	Property, plant and equipment
	Equipment and software	$	345.4		$	342.5
	Equipment under customer usage agreements	288.6			285.2
	Building and improvements	179.5			176.9
	Leasehold improvements	59.7			63.2
	Land	51.5			51.6
	Furniture and fixtures	16.4			16.3
		941.1			935.7
	Less – accumulated depreciation and amortization	(482.9		)	(473.8		)
		$	458.2		$	461.9

Business_Segments_and_Geograph1

Business Segments and Geographic Information (Tables)	3 Months Ended
	Dec. 27, 2014
Segment Reporting [Abstract]
Segment Information	Segment information is as follows:
		Three Months Ended
		December 27,			December 28,
		2014			2013
	Total revenues:
	Diagnostics	$	304.1		$	285.7
	Breast Health	242			226.5
	GYN Surgical	84.4			78.9
	Skeletal Health	22.3			21.4
		$	652.8		$	612.5
	Operating income:
	Diagnostics	$	28.2		$	4.8
	Breast Health	60.6			43.8
	GYN Surgical	13.1			11.1
	Skeletal Health	1.6			1.6
		$	103.5		$	61.3
	Depreciation and amortization:
	Diagnostics	$	88.6		$	92.2
	Breast Health	7.6			9.4
	GYN Surgical	25.6			26
	Skeletal Health	0.2			0.2
		$	122		$	127.8
	Capital expenditures:
	Diagnostics	$	14.8		$	10.3
	Breast Health	2.6			1.8
	GYN Surgical	2			1.8
	Skeletal Health	0.2			0.1
	Corporate	1.5			2.4
		$	21.1		$	16.4
		December 27,			September 27,
		2014			2014
	Identifiable assets:
	Diagnostics	$	4,294.50		$	4,383.50
	Breast Health	847.3			859.8
	GYN Surgical	1,726.80			1,748.20
	Skeletal Health	25.1			26.1
	Corporate	1,184.40			1,397.10
		$	8,078.10		$	8,414.70
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows:
		Three Months Ended
		December 27,		December 28,
		2014		2013
	United States	74	%	75	%
	Europe	13	%	14	%
	Asia-Pacific	9	%	7	%
	All others	4	%	4	%
		100	%	100	%

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Dec. 27, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following:
	Description	As of December 27, 2014				As of September 27, 2014
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Value				Value
	Developed technology	$	3,965.20	$	1,464.20	$	3,951.10	$	1,390.50
	In-process research and development	3.7		—		17.9		—
	Customer relationships and contracts	1,102.30		405.7		1,102.40		384.7
	Trade names	236.4		111.8		236.5		105.3
	Patents	14.6		9		14.5		8.9
	Business licenses	2.6		2		2.6		2
		$	5,324.80	$	1,992.70	$	5,325.00	$	1,891.40
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense as of December 27, 2014 for each of the five succeeding fiscal years is as follows:
	Remainder of Fiscal 2015	$	302.6
	Fiscal 2016	$	375.9
	Fiscal 2017	$	366.8
	Fiscal 2018	$	356.3
	Fiscal 2019	$	344.4

Product_Warranties_Tables

Product Warranties (Tables)	3 Months Ended
	Dec. 27, 2014
Guarantees [Abstract]
Product Warranty	Product warranty activity was as follows:
		Balance at		Provisions		Settlements/			Balance at
		Beginning of				Adjustments			End of Period
		Period
	Three Months Ended:
	27-Dec-14	$	6.3	$	1.5	$	(1.8	)	$	6
	28-Dec-13	$	9.3	$	2	$	(2.4	)	$	8.9

Supplemental_Guarantor_Condens1

Supplemental Guarantor Condensed Consolidating Financials (Tables)	3 Months Ended
	Dec. 27, 2014
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Schedule of Supplemental Condensed Consolidating Statement of Operations	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended December 27, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	131.6		$	425.8		$	120		$	(130.8	)	$	546.6
	Service and other	91			15.6			12.1			(12.5		)	106.2
		222.6			441.4			132.1			(143.3		)	652.8
	Costs of revenues:
	Product	58.3			170.9			88.3			(130.8		)	186.7
	Amortization of intangible assets	1.6			72.2			0.1			—			73.9
	Service and other	35.2			16.1			14.8			(12.5		)	53.6
	Gross Profit	127.5			182.2			28.9			—			338.6
	Operating expenses:
	Research and development	8.4			42			1.6			—			52
	Selling and marketing	24.4			40.5			21.1			—			86
	General and administrative	17.4			35.2			8.7			—			61.3
	Amortization of intangible assets	0.6			26.2			1			—			27.8
	Restructuring and divestiture charges	1.8			0.5			5.7			—			8
		52.6			144.4			38.1			—			235.1
	Income (loss) from operations	74.9			37.8			(9.2		)	—			103.5
	Interest income	(0.7		)	1.1			0.2			(0.2		)	0.4
	Interest expense	(51.8		)	(0.3		)	(0.6		)	0.2			(52.5		)
	Debt extinguishment loss	(6.7		)	—			—			—			(6.7		)
	Other (expense) income, net	50.7			(51.3		)	0.1			(0.1		)	(0.6		)
	Income (loss) before income taxes	66.4			(12.7		)	(9.5		)	(0.1		)	44.1
	Provision for income taxes	1.4			12.3			1.2			—			14.9
	Equity in earnings (losses) of subsidiaries	(35.8		)	2			—			33.8			—
	Net income (loss)	$	29.2		$	(23.0	)	$	(10.7	)	$	33.7		$	29.2
	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
	For the Three Months Ended December 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Revenues:
	Product	$	105.5		$	381.5		$	126.4		$	(101.0	)	$	512.4
	Service and other	85.9			15.9			11.8			(13.5		)	100.1
		191.4			397.4			138.2			(114.5		)	612.5
	Costs of revenues:
	Product	52.9			138.8			86.3			(101.1		)	176.9
	Amortization of intangible assets	1.4			74.1			1.2			—			76.7
	Service and other	42.3			7.6			16.8			(13.4		)	53.3
	Gross profit	94.8			176.9			33.9			—			305.6
	Operating expenses:
	Research and development	7.5			38.9			2.3			—			48.7
	Selling and marketing	17.9			42.8			22.6			—			83.3
	General and administrative	14.7			41.5			11.6			—			67.8
	Amortization of intangible assets	0.8			24.1			1.3			—			26.2
	Restructuring and divestiture charges	5			9.7			3.6			—			18.3
		45.9			157			41.4			—			244.3
	Income from operations	48.9			19.9			(7.5		)	—			61.3
	Interest income	0.1			0.3			0.1			(0.2		)	0.3
	Interest expense	(60.7		)	(0.3		)	(0.5		)	0.2			(61.3		)
	Debt extinguishment loss	(2.9		)	—			—			—			(2.9		)
	Other (expense) income, net	9.6			(9.3		)	0.9			—			1.2
	(Loss) income before income taxes	(5.0		)	10.6			(7.0		)	—			(1.4		)
	Provision (benefit) for income taxes	(0.1		)	1.6			2.4			—			3.9
	Equity in earnings (losses) of subsidiaries	(0.4		)	10.1			—			(9.7		)	—
	Net income (loss)	$	(5.3	)	$	19.1		$	(9.4	)	$	(9.7	)	$	(5.3	)
Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income	SUPPLEMENTAL CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
	For the Three Months Ended December 27, 2014
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net income (loss)	$	29.2		$	(23.0	)	$	(10.7	)	$	33.7		$	29.2
	Changes in foreign currency translation adjustment	—			(0.3		)	(8.7		)	—			(9.0		)
	Changes in unrealized holding gain on available-for-sale securities	—			5.1			—			—			5.1
	Changes in pension plans, net of taxes	—			—			0.1			—			0.1
	Comprehensive income (loss)	$	29.2		$	(18.2	)	$	(19.3	)	$	33.7		$	25.4
	For the Three Months Ended December 28, 2013
		Parent/Issuer			Guarantor			Non-Guarantor			Eliminations			Consolidated
					Subsidiaries			Subsidiaries
	Net income (loss)	$	(5.3	)	$	19.1		$	(9.4	)	$	(9.7	)	$	(5.3	)
	Changes in foreign currency translation adjustment	—			0.1			(1.3		)	—			(1.2		)
	Changes in unrealized holding loss on available-for-sale securities	—			(1.2		)	—			—			(1.2		)
	Changes in pension plans, net of taxes	—			—			(0.6		)	—			(0.6		)
	Comprehensive income (loss)	$	(5.3	)	$	18		$	(11.3	)	$	(9.7	)	$	(8.3	)
Schedule of Supplemental Condensed Consolidating Balance Sheet	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	December 27, 2014
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	150.6		$	249.4		$	144		$	—		$	544
	Restricted cash	—			—			5.1			—			5.1
	Accounts receivable, net	116.2			198.2			86.1			—			400.5
	Inventories	88			174.6			47.7			—			310.3
	Deferred income tax assets	26.3			11.7			1			—			39
	Prepaid income taxes	—			3.1			—			(3.1		)	—
	Prepaid expenses and other current assets	18.5			10			9.2			—			37.7
	Intercompany receivables	—			2,787.90			19			(2,806.9		)	—
	Total current assets	399.6			3,434.90			312.1			(2,810.0		)	1,336.60
	Property, plant and equipment, net	27.8			337.7			92.7			—			458.2
	Intangible assets, net	23.6			3,279.00			40.1			(10.6		)	3,332.10
	Goodwill	327.8			2,390.80			91.3			—			2,809.90
	Other assets	82.7			57.3			1.3			—			141.3
	Long term intercompany receivables	—			—			13			(13.0		)	—
	Investment in subsidiaries	8,490.00			216.6			—			(8,706.6		)	—
	Total assets	$	9,351.50		$	9,716.30		$	550.5		$	(11,540.2	)	$	8,078.10
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	139.4		$	—		$	—		$	—		$	139.4
	Accounts payable	26.9			32.7			7.4			—			67
	Accrued expenses	156.3			48.4			51.4			(3.1		)	253
	Deferred revenue	111			8.3			29.1			—			148.4
	Intercompany payables	2,763.90			—			43.2			(2,807.1		)	—
	Total current liabilities	3,197.50			89.4			131.1			(2,810.2		)	607.8
	Long-term debt, net of current portion	3,815.40			—			—			—			3,815.40
	Deferred income tax liabilities	97.3			1,244.40			4			—			1,345.70
	Deferred service obligations – long-term	8.6			3.9			7.3			—			19.8
	Long-term intercompany payables	13			—			—			(13.0		)	—
	Other long-term liabilities	117.3			33			36.7			—			187
	Total stockholders’ equity	2,102.40			8,345.60			371.4			(8,717.0		)	2,102.40
	Total liabilities and stockholders’ equity	$	9,351.50		$	9,716.30		$	550.5		$	(11,540.2	)	$	8,078.10
	SUPPLEMENTAL CONDENSED CONSOLIDATING BALANCE SHEET
	September 27, 2014
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	ASSETS
	Current assets:
	Cash and cash equivalents	$	288.1		$	287.8		$	160.2		$	—		$	736.1
	Restricted cash	—			—			5.5			—			5.5
	Accounts receivable, net	128.4			182.5			85.1			—			396
	Inventories	88.6			190.1			51.9			—			330.6
	Deferred income tax assets	26.2			12.1			1.1			—			39.4
	Prepaid income taxes	20.3			3.2			—			(1.1		)	22.4
	Prepaid expenses and other current assets	16.2			11			8.6			—			35.8
	Intercompany receivables	—			2,702.10			18.1			(2,720.2		)	—
	Total current assets	567.8			3,388.80			330.5			(2,721.3		)	1,565.80
	Property, plant and equipment, net	29.7			337.1			95.1			—			461.9
	Intangible assets, net	25.1			3,377.30			41.9			(10.7		)	3,433.60
	Goodwill	282.4			2,390.90			137.5			—			2,810.80
	Other assets	88.4			52.7			1.5			—			142.6
	Long term intercompany receivables	—			—			13			(13.0		)	—
	Investments in subsidiaries	8,526.00			221.7			—			(8,747.7		)	—
	Total assets	$	9,519.40		$	9,768.50		$	619.5		$	(11,492.7	)	$	8,414.70
	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Current liabilities:
	Current portion of long-term debt	$	114.5		$	—		$	—		$	—		$	114.5
	Accounts payable	34.8			46.1			11.2			—			92.1
	Accrued expenses	139.4			69.5			54.3			(1.1		)	262.1
Deferred revenue	113.5			7.4			30			—			150.9
Intercompany payables	2,676.20			—			44.2			(2,720.4		)	—
Total current liabilities	3,078.40			123			139.7			(2,721.5		)	619.6
Long-term debt, net of current portion	4,153.20			—			—			—			4,153.20
Deferred income tax liabilities	90.9			1,279.10			5.4			—			1,375.40
Deferred service obligations – long-term	8.3			3.6			8.2			—			20.1
Long-term intercompany payables	13			—			—			(13.0		)	—
Other long-term liabilities	112.6			34.3			36.5			—			183.4
Total stockholders’ equity	2,063.00			8,328.50			429.7			(8,758.2		)	2,063.00
Total liabilities and stockholders’ equity	$	9,519.40		$	9,768.50		$	619.5		$	(11,492.7	)	$	8,414.70
Schedule of Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS
	For the Three Months Ended December 27, 2014
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by (used in) operating activities	$	186.9		$	(25.9	)	$	(7.5	)	$	—		$	153.5
	INVESTING ACTIVITIES
	Purchase of property and equipment	(2.4		)	(5.6		)	(2.8		)	—			(10.8		)
	Increase in equipment under customer usage agreements	—			(6.5		)	(3.8		)	—			(10.3		)
	Net purchases of insurance contracts	(6.4		)	—			—			—			(6.4		)
	Sales of mutual funds	6.4			—			—			—			6.4
	Increase in other assets	(0.8		)	(0.1		)	—			—			(0.9		)
	Net cash used in investing activities	(3.2		)	(12.2		)	(6.6		)	—			(22.0		)
	FINANCING ACTIVITIES
	Repayment of long-term debt	(328.8		)	—			—			—			(328.8		)
	Net proceeds from issuance of common stock pursuant to employee stock plans	15.2			—			—			—			15.2
	Excess tax benefit related to equity awards	3			—			—			—			3
	Payment of minimum tax withholdings on net share settlement of equity awards	(10.6		)	—			—			—			(10.6		)
	Net cash used in financing activities	(321.2		)	—			—			—			(321.2		)
	Effect of exchange rate changes on cash and cash equivalents	—			(0.3		)	(2.1		)	—			(2.4		)
	Net decrease in cash and cash equivalents	(137.5		)	(38.4		)	(16.2		)	—			(192.1		)
	Cash and cash equivalents, beginning of period	288.1			287.8			160.2			—			736.1
	Cash and cash equivalents, end of period	$	150.6		$	249.4		$	144		$	—		$	544
	CONSOLIDATING STATEMENT OF CASH FLOWS
	For the Three Months Ended December 28, 2013
		Parent/			Guarantor			Non-Guarantor			Eliminations			Consolidated
		Issuer			Subsidiaries			Subsidiaries
	OPERATING ACTIVITIES
	Net cash provided by operating activities	$	301.6		$	(142.0	)	$	(10.3	)	$	—		$	149.3
	INVESTING ACTIVITIES
	Net proceeds from sale of business	—			—			2.4			—			2.4
	Purchase of property and equipment	(2.9		)	(3.2		)	(2.3		)	—			(8.4		)
	Increase in equipment under customer usage agreements	(0.4		)	(4.3		)	(3.3		)	—			(8.0		)
	Net sales of insurance contracts	13.8			—			—			—			13.8
	Purchases of mutual funds	(29.7		)	—			—			—			(29.7		)
	Sales of mutual funds	15.9			—			—			—			15.9
	(Increase) decrease in other assets	0.1			(1.0		)	0.5			—			(0.4		)
	Net cash provided by (used in) investing activities	(3.2		)	(8.5		)	(2.7		)	—			(14.4		)
	FINANCING ACTIVITIES
	Repayment of long-term debt	(521.3		)	—			—			—			(521.3		)
	Net proceeds from issuance of common stock pursuant to employee stock plans	12.9			—			—			—			12.9
	Excess tax benefit related to equity awards	3			—			—			—			3
	Payment of minimum tax withholdings on net share settlements of equity awards	(9.1		)	—			—			—			(9.1		)
	Net cash used in financing activities	(514.5		)	—			—			—			(514.5		)
	Effect of exchange rate changes on cash and cash equivalents	—			0.1			(0.5		)	—			(0.4		)
	Net decrease in cash and cash equivalents	(216.1		)	(150.4		)	(13.5		)	—			(380.0		)
	Cash and cash equivalents, beginning of period	321.5			387.4			113.5			—			822.5
	Cash and cash equivalents, end of period	$	105.4		$	237		$	100		$	—		$	442.5

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 27, 2014
In Millions, unless otherwise specified
Assets:
Assets measured at fair value on a recurring basis	$38.90
Liabilities:
Liabilities measured at fair value on a recurring basis	37.1
Equity securities
Assets:
Assets measured at fair value on a recurring basis	29.5
Mutual funds
Assets:
Assets measured at fair value on a recurring basis	9.4
Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	37.1
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	38.9
Liabilities:
Liabilities measured at fair value on a recurring basis	37.1
Quoted Prices in Active Market for Identical Assets (Level 1) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	29.5
Quoted Prices in Active Market for Identical Assets (Level 1) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	9.4
Quoted Prices in Active Market for Identical Assets (Level 1) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	37.1
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	$0

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended
	Dec. 28, 2013	Dec. 27, 2014	Sep. 27, 2014
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Asset impairment charge	$3,100,000
Cost-method equity investments in non-publicly traded securities		5,200,000	5,200,000
Equity Security Other Than Temporary Impairment Charge	700,000
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal under credit agreement		1,720,000,000
Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument		$1,040,000,000

Fair_Value_Measurements_Estima

Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail) (USD $)	Dec. 27, 2014
In Millions, unless otherwise specified
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	$1,530.80
2010 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	566.9
2012 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	555.6
2013 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	$408.30

Restructuring_and_Divestiture_2

Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013	Sep. 27, 2014
Restructuring Cost and Reserve [Line Items]
Fiscal restructuring and divestiture charges	$8	$18.30
Restructuring | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			42.2
Non-cash impairment charge			3.1
Facility closure costs			0.6
Other			0.3
Fiscal restructuring charges			46.2
Divestiture net charges			5.5
Fiscal restructuring and divestiture charges			51.7
Restructuring | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions	7.3
Facility closure costs	0.7
Fiscal restructuring charges	8
Restructuring | Consolidation of Diagnostics Operations | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			2.9
Non-cash impairment charge			0
Facility closure costs			0
Other			0.1
Fiscal restructuring charges			3
Restructuring | Consolidation of Diagnostics Operations | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions	0.1
Facility closure costs	0.4
Fiscal restructuring charges	0.5
Restructuring | Fiscal 2015 Actions | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0
Non-cash impairment charge			0
Facility closure costs			0
Other			0
Fiscal restructuring charges			0
Restructuring | Fiscal 2015 Actions | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions	2.5
Facility closure costs	0
Fiscal restructuring charges	2.5
Restructuring | Fiscal 2014 Actions | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			29.5
Non-cash impairment charge			0
Facility closure costs			0
Other			0
Fiscal restructuring charges			29.5
Restructuring | Fiscal 2014 Actions | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions	4.5
Facility closure costs	0.2
Fiscal restructuring charges	4.7
Restructuring | Other Operating Cost Reductions | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			9.8
Non-cash impairment charge		3.1	3.1
Facility closure costs			0.6
Other			0.2
Fiscal restructuring charges			13.7
Restructuring | Other Operating Cost Reductions | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions	0.2
Facility closure costs	0.1
Fiscal restructuring charges	$0.30

Restructuring_and_Divestiture_3

Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) (Restructuring, USD $)	12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Sep. 27, 2014	Dec. 27, 2014
Fiscal 2014 Charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	$46.20
Period end balance	16.9
Fiscal 2014 Charges | Consolidation of Diagnostics Operations
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	3
Period end balance	3
Fiscal 2014 Charges | Fiscal 2015 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	0
Period end balance	0
Fiscal 2014 Charges | Fiscal 2014 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	29.5
Period end balance	12
Fiscal 2014 Charges | Other Operating Cost Reductions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges	13.7
Period end balance	1.9
Fiscal 2015 Charges
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges		8
Stock-based compensation		-0.1
Fiscal 2015 Charges | Consolidation of Diagnostics Operations
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges		0.5
Fiscal 2015 Charges | Fiscal 2015 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges		2.5
Fiscal 2015 Charges | Fiscal 2014 Actions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges		4.7
Fiscal 2015 Charges | Other Operating Cost Reductions
Restructuring Reserve [Roll Forward]
Fiscal restructuring charges		0.3
Two Thousand Fifteen
Restructuring Reserve [Roll Forward]
Stock-based compensation		-0.1
Severance payments		-10
Other payments		-1
Period end balance		13.8
Two Thousand Fifteen | Consolidation of Diagnostics Operations
Restructuring Reserve [Roll Forward]
Stock-based compensation		0
Severance payments		-2.4
Other payments		-0.4
Period end balance		0.7
Two Thousand Fifteen | Fiscal 2015 Actions
Restructuring Reserve [Roll Forward]
Stock-based compensation		-0.1
Severance payments		-0.4
Other payments		0
Period end balance		2
Two Thousand Fifteen | Fiscal 2014 Actions
Restructuring Reserve [Roll Forward]
Stock-based compensation		0
Severance payments		-6.5
Other payments		-0.4
Period end balance		9.8
Two Thousand Fifteen | Other Operating Cost Reductions
Restructuring Reserve [Roll Forward]
Stock-based compensation		0
Severance payments		-0.7
Other payments		-0.2
Period end balance		$1.30

Restructuring_and_Divestiture_4

Restructuring and Divestiture Charges - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended	3 Months Ended
	Sep. 27, 2014	Dec. 27, 2014	Sep. 27, 2014	Dec. 28, 2013	Mar. 29, 2014
Restructuring Cost and Reserve [Line Items]
Estimated aggregate severance charges		$1,800,000
Gain (Loss) on Disposition of Business	5,300,000
Restructuring | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Severance charges		2,500,000
Share Based Compensation Expense Included Other Restructuring Costs		100,000
Workforce reductions		7,300,000
Facility closure costs		700,000
Restructuring | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			42,200,000
Facility closure costs			600,000
Non-cash impairment charge			3,100,000
Consolidation of Diagnostics Operations | Molecular Diagnostics Operations
Restructuring Cost and Reserve [Line Items]
Severance and benefits and facility closure costs		500,000
Severance charges			3,000,000	800,000
Consolidation of Diagnostics Operations | Restructuring | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		100,000
Facility closure costs		400,000
Consolidation of Diagnostics Operations | Restructuring | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			2,900,000
Facility closure costs			0
Non-cash impairment charge			0
Fiscal 2014 Actions
Restructuring Cost and Reserve [Line Items]
Severance charges			16,600,000	6,300,000
Compensation charges			1,800,000	400,000
Fiscal 2014 Actions | Jack Cumming
Restructuring Cost and Reserve [Line Items]
Severance charges				6,600,000
Compensation charges				4,400,000
Fiscal 2014 Actions | Restructuring | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions		4,500,000
Facility closure costs		200,000
Fiscal 2014 Actions | Restructuring | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			29,500,000
Facility closure costs			0
Non-cash impairment charge			0
Other Operating Cost Reductions
Restructuring Cost and Reserve [Line Items]
Severance charges			8,700,000		0
Estimated aggregate severance charges				9,500,000
Number of employees affected for severance benefits				95
Other Operating Cost Reductions | Restructuring | Fiscal 2015 Charges
Restructuring Cost and Reserve [Line Items]
Severance and benefits and facility closure costs		300,000
Workforce reductions		200,000
Facility closure costs		100,000
Other Operating Cost Reductions | Restructuring | Fiscal 2014 Charges
Restructuring Cost and Reserve [Line Items]
Workforce reductions			9,800,000
Facility closure costs			600,000
Non-cash impairment charge			$3,100,000	$3,100,000

Borrowings_and_Credit_Arrangem2

Borrowings and Credit Arrangements - Company's Borrowings (Detail) (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	$139.40	$114.50
Convertible Notes	1,248.30	1,235.60
Total long-term debt obligations	3,815.40	4,153.20
Total debt obligations	3,954.80	4,267.70
Term Loan A
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	124.5	99.6
Long-term debt obligations, net of debt discount	747.1	796.7
Term Loan B
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	14.9	14.9
Long-term debt obligations, net of debt discount	820	1,120.90
Senior Notes
Debt Instrument [Line Items]
Long-term debt obligations, net of debt discount	$1,000	$1,000

Borrowings_and_Credit_Arrangem3

Borrowings and Credit Arrangements - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended
In Millions, unless otherwise specified	Dec. 24, 2014	Oct. 31, 2013	Dec. 27, 2014	Dec. 28, 2013
Debt Instrument [Line Items]
Debt extinguishment loss			$6.70	$2.90
Non-cash interest expense amortization of debt discount and deferred financing costs			16.7	19.7
Number of financial ratio covenants			2
Credit Agreement
Debt Instrument [Line Items]
Weighted average interest rates, Borrowings outstanding under the credit agreement			2.77%	3.06%
Interest expense			17.6	20.4
Non-cash interest expense amortization of debt discount and deferred financing costs			3.1	3.3
Senior Notes
Debt Instrument [Line Items]
Interest expense			16	16
Non-cash interest expense amortization of debt discount and deferred financing costs			0.4	0.4
Senior note interest rate per year			6.25%
Term Loan B | Credit Agreement
Debt Instrument [Line Items]
Prepaid principal amount	300	100
Debt extinguishment loss			$6.70	$2.90
Interest rates under Term Loans			3.25%
Term Loan A | Credit Agreement
Debt Instrument [Line Items]
Interest rates under Term Loans			2.16%

Borrowings_and_Credit_Arrangem4

Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Debt Conversion [Line Items]
Non-cash interest expense	$16.70	$19.70
Convertible Notes Payable
Debt Conversion [Line Items]
Amortization of debt discount	8.8	11.5
Amortization of deferred financing costs	0.4	0.7
Principal accretion	3.9	3.8
Non-cash interest expense	13.1	16
2.00% accrued interest (cash)	4.8	8.1
Convertible Notes Interest Expense	2.00%	2.00%
Interest expense, net	$17.90	$24.10

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Oct. 29, 2013	Sep. 04, 2012
Commitments and Contingencies Disclosure [Abstract]
Assessed damages		$4
Additional Payments	$14.70

Marketable_Securities_Reconcil

Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail) (Equity securities, USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Equity securities
Schedule Of Marketable Securities [Line Items]
Cost	$15.50	$15.50
Gross Unrealized Gains	19.7	10.2
Gross Unrealized Losses	-5.7	-1.3
Fair Value	$29.50	$24.40

Net_Income_Loss_Per_Share_Reco

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding (in shares)	278,671	272,708
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units (in shares)	2,464	0
Incremental shares from assumed conversion of the Convertible Notes premium (in shares)	2,041	0
Diluted weighted average common shares outstanding (in shares)	283,176	272,708
Outstanding Stock Options
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	3,782	7,199
Restricted stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	140	950

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$12.10	$13.70
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2	1.5
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1.9	1.9
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2	1.7
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	6.1	3.8
Restructuring and divestiture
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$0.10	$4.80

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units	1.3	2
Restricted stock units (RSUs), weighted average grant date fair values	$26.17	$21.51
Unvested RSUs outstanding	4
Unvested RSUs weighted-average grant date fair value	$22.95
Unrecognized compensation expense	$90.50
Weighted-average period for recognition of unrecognized stock-based compensation, years	3 years
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units	0.3
Restricted stock units (RSUs), weighted average grant date fair values	$26.21
Minimum eligible percentage to receive target number of shares of company's common stock	0.00%
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
Performance stock units vesting period	3 years
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	1	2
Weighted-average exercise prices	$26.12	$21.82
Share-based compensation, stock option outstanding	9.2
Weighted-average exercise price of options outstanding	$21.34
Unrecognized compensation expense	$29.40
Weighted-average period for recognition of unrecognized stock-based compensation, years	3 years 8 months 12 days

StockBased_Compensation_Weight

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) (Employee Stock Purchase Plan, USD $)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.70%	1.20%
Expected volatility	38.60%	41.40%
Expected life (in years)	5 years 3 months 3 days	4 years 4 months 24 days
Dividend yield	$0	$0
Weighted average fair value of options granted	$9.44	$7.64

Other_Balance_Sheet_Informatio2

Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail) (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Raw materials	$112	$115.60
Work-in-process	53	57.1
Finished goods	145.3	157.9
Inventories	$310.30	$330.60

Other_Balance_Sheet_Informatio3

Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail) (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Equipment and software	$345.40	$342.50
Equipment under customer usage agreements	288.6	285.2
Building and improvements	179.5	176.9
Leasehold improvements	59.7	63.2
Land	51.5	51.6
Furniture and fixtures	16.4	16.3
Property, plant and equipment, gross	941.1	935.7
Less – accumulated depreciation and amortization	-482.9	-473.8
Property, plant and equipment, net	$458.20	$461.90

Business_Segments_and_Geograph2

Business Segments and Geographic Information - Additional Information (Detail) (USD $)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013	Sep. 27, 2014
	Customer	Customer	Customer
	Segment
Segment Reporting Disclosure [Line Items]
Number of reportable segments	4
Number of reportable segments	4
Revenues	$652,800,000	$612,500,000
Customers with balances greater than 10% of accounts receivable	0		0
Customer represented greater than 10% of consolidated revenues	0	0
Countries with greater than 10% of consolidated revenue	0
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$0	$0

Business_Segments_and_Geograph3

Business Segments and Geographic Information - Segment Information (Detail) (USD $)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013	Sep. 27, 2014
Segment Reporting Information [Line Items]
Total revenues	$652,800,000	$612,500,000
Operating income (loss)	103,500,000	61,300,000
Depreciation and amortization	122,000,000	127,800,000
Capital expenditures	21,100,000	16,400,000
Identifiable assets	8,078,100,000		8,414,700,000
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	304,100,000	285,700,000
Operating income (loss)	28,200,000	4,800,000
Depreciation and amortization	88,600,000	92,200,000
Capital expenditures	14,800,000	10,300,000
Identifiable assets	4,294,500,000		4,383,500,000
Breast Health
Segment Reporting Information [Line Items]
Total revenues	242,000,000	226,500,000
Operating income (loss)	60,600,000	43,800,000
Depreciation and amortization	7,600,000	9,400,000
Capital expenditures	2,600,000	1,800,000
Identifiable assets	847,300,000		859,800,000
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	84,400,000	78,900,000
Operating income (loss)	13,100,000	11,100,000
Depreciation and amortization	25,600,000	26,000,000
Capital expenditures	2,000,000	1,800,000
Identifiable assets	1,726,800,000		1,748,200,000
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	22,300,000	21,400,000
Operating income (loss)	1,600,000	1,600,000
Depreciation and amortization	200,000	200,000
Capital expenditures	200,000	100,000
Identifiable assets	25,100,000		26,100,000
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	1,500,000	2,400,000
Identifiable assets	$1,184,400,000		$1,397,100,000

Business_Segments_and_Geograph4

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013
Schedule Of Geographical Segments [Line Items]
Revenues	100.00%	100.00%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	74.00%	75.00%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	13.00%	14.00%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	9.00%	7.00%
All others
Schedule Of Geographical Segments [Line Items]
Revenues	4.00%	4.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013
Income Tax Disclosure [Abstract]
Company's effective tax rate	33.80%	-277.10%

Intangible_Assets_Schedule_of_

Intangible Assets - Schedule of Intangible Assets (Detail) (USD $)	Dec. 27, 2014	Sep. 27, 2014
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$5,324.80	$5,325
Accumulated Amortization	1,992.70	1,891.40
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,965.20	3,951.10
Accumulated Amortization	1,464.20	1,390.50
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3.7	17.9
Accumulated Amortization	0	0
Customer relationships and contracts
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,102.30	1,102.40
Accumulated Amortization	405.7	384.7
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	236.4	236.5
Accumulated Amortization	111.8	105.3
Patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	14.6	14.5
Accumulated Amortization	9	8.9
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2.6	2.6
Accumulated Amortization	$2	$2

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (Developed technology, USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014
Developed technology
Finite-Lived Intangible Assets [Line Items]
IPR&D Asset reclassified to Developed Technology	$14.20

Intangible_Assets_Schedule_of_1

Intangible Assets - Schedule of Estimated Amortization Expense (Detail) (USD $)	Dec. 27, 2014
In Millions, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2015	$302.60
Fiscal 2016	375.9
Fiscal 2017	366.8
Fiscal 2018	356.3
Fiscal 2019	$344.40

Product_Warranties_Product_War

Product Warranties - Product Warranty (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$6.30	$9.30
Provisions	1.5	2
Settlements/ Adjustments	-1.8	-2.4
Balance at End of Period	$6	$8.90

Supplemental_Guarantor_Condens2

Supplemental Guarantor Condensed Consolidating Financials - Additional Information (Detail) (Parent/Issuer)	3 Months Ended
	Dec. 27, 2014
Parent/Issuer
Condensed Financial Statements, Captions [Line Items]
Ownership percentage in domestic subsidiaries	100.00%

Supplemental_Guarantor_Condens3

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Statement of Operations (Detail) (USD $)	3 Months Ended
	Dec. 27, 2014	Dec. 28, 2013
Revenues:
Product	$546,600,000	$512,400,000
Service and other	106,200,000	100,100,000
Revenues	652,800,000	612,500,000
Costs of revenues:
Product	186,700,000	176,900,000
Amortization of intangible assets	73,900,000	76,700,000
Service and other	53,600,000	53,300,000
Gross Profit	338,600,000	305,600,000
Operating expenses:
Research and development	52,000,000	48,700,000
Selling and marketing	86,000,000	83,300,000
General and administrative	61,300,000	67,800,000
Amortization of intangible assets	27,800,000	26,200,000
Restructuring and divestiture charges	8,000,000	18,300,000
Operating expenses	235,100,000	244,300,000
Income from operations	103,500,000	61,300,000
Interest income	400,000	300,000
Interest expense	-52,500,000	-61,300,000
Debt extinguishment loss	-6,700,000	-2,900,000
Other (expense) income, net	-600,000	1,200,000
Income (loss) before income taxes	44,100,000	-1,400,000
Provision for income taxes	14,900,000	3,900,000
Equity in earnings (losses) of subsidiaries	0	0
Net income (loss)	29,200,000	-5,300,000
Eliminations
Revenues:
Product	-130,800,000	-101,000,000
Service and other	-12,500,000	-13,500,000
Revenues	-143,300,000	-114,500,000
Costs of revenues:
Product	-130,800,000	-101,100,000
Amortization of intangible assets	0	0
Service and other	-12,500,000	-13,400,000
Gross Profit	0	0
Operating expenses:
Research and development	0	0
Selling and marketing	0	0
General and administrative	0	0
Amortization of intangible assets	0	0
Restructuring and divestiture charges	0	0
Operating expenses	0	0
Income from operations	0	0
Interest income	-200,000	-200,000
Interest expense	200,000	200,000
Debt extinguishment loss	0	0
Other (expense) income, net	-100,000	0
Income (loss) before income taxes	-100,000	0
Provision for income taxes	0	0
Equity in earnings (losses) of subsidiaries	33,800,000	-9,700,000
Net income (loss)	33,700,000	-9,700,000
Parent/Issuer
Revenues:
Product	131,600,000	105,500,000
Service and other	91,000,000	85,900,000
Revenues	222,600,000	191,400,000
Costs of revenues:
Product	58,300,000	52,900,000
Amortization of intangible assets	1,600,000	1,400,000
Service and other	35,200,000	42,300,000
Gross Profit	127,500,000	94,800,000
Operating expenses:
Research and development	8,400,000	7,500,000
Selling and marketing	24,400,000	17,900,000
General and administrative	17,400,000	14,700,000
Amortization of intangible assets	600,000	800,000
Restructuring and divestiture charges	1,800,000	5,000,000
Operating expenses	52,600,000	45,900,000
Income from operations	74,900,000	48,900,000
Interest income	-700,000	100,000
Interest expense	-51,800,000	-60,700,000
Debt extinguishment loss	-6,700,000	-2,900,000
Other (expense) income, net	50,700,000	9,600,000
Income (loss) before income taxes	66,400,000	-5,000,000
Provision for income taxes	1,400,000	-100,000
Equity in earnings (losses) of subsidiaries	-35,800,000	-400,000
Net income (loss)	29,200,000	-5,300,000
Guarantor Subsidiaries
Revenues:
Product	425,800,000	381,500,000
Service and other	15,600,000	15,900,000
Revenues	441,400,000	397,400,000
Costs of revenues:
Product	170,900,000	138,800,000
Amortization of intangible assets	72,200,000	74,100,000
Service and other	16,100,000	7,600,000
Gross Profit	182,200,000	176,900,000
Operating expenses:
Research and development	42,000,000	38,900,000
Selling and marketing	40,500,000	42,800,000
General and administrative	35,200,000	41,500,000
Amortization of intangible assets	26,200,000	24,100,000
Restructuring and divestiture charges	500,000	9,700,000
Operating expenses	144,400,000	157,000,000
Income from operations	37,800,000	19,900,000
Interest income	1,100,000	300,000
Interest expense	-300,000	-300,000
Debt extinguishment loss	0	0
Other (expense) income, net	-51,300,000	-9,300,000
Income (loss) before income taxes	-12,700,000	10,600,000
Provision for income taxes	12,300,000	1,600,000
Equity in earnings (losses) of subsidiaries	2,000,000	10,100,000
Net income (loss)	-23,000,000	19,100,000
Non-Guarantor Subsidiaries
Revenues:
Product	120,000,000	126,400,000
Service and other	12,100,000	11,800,000
Revenues	132,100,000	138,200,000
Costs of revenues:
Product	88,300,000	86,300,000
Amortization of intangible assets	100,000	1,200,000
Service and other	14,800,000	16,800,000
Gross Profit	28,900,000	33,900,000
Operating expenses:
Research and development	1,600,000	2,300,000
Selling and marketing	21,100,000	22,600,000
General and administrative	8,700,000	11,600,000
Amortization of intangible assets	1,000,000	1,300,000
Restructuring and divestiture charges	5,700,000	3,600,000
Operating expenses	38,100,000	41,400,000
Income from operations	-9,200,000	-7,500,000
Interest income	200,000	100,000
Interest expense	-600,000	-500,000
Debt extinguishment loss	0	0
Other (expense) income, net	100,000	900,000
Income (loss) before income taxes	-9,500,000	-7,000,000
Provision for income taxes	1,200,000	2,400,000
Equity in earnings (losses) of subsidiaries	0	0
Net income (loss)	($10,700,000)	($9,400,000)

Supplemental_Guarantor_Condens4

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Statements of Comprehensive (Loss) Income (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$29.20	($5.30)
Changes in foreign currency translation adjustment	-9	-1.2
Changes in unrealized holding gain on available-for-sale securities	5.1	-1.2
Changes in pension plans, net of taxes	0.1	-0.6
Comprehensive income (loss)	25.4	-8.3
Eliminations
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	33.7	-9.7
Changes in foreign currency translation adjustment	0	0
Changes in unrealized holding gain on available-for-sale securities	0	0
Changes in pension plans, net of taxes	0	0
Comprehensive income (loss)	33.7	-9.7
Parent/Issuer
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	29.2	-5.3
Changes in foreign currency translation adjustment	0	0
Changes in unrealized holding gain on available-for-sale securities	0	0
Changes in pension plans, net of taxes	0	0
Comprehensive income (loss)	29.2	-5.3
Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	-23	19.1
Changes in foreign currency translation adjustment	-0.3	0.1
Changes in unrealized holding gain on available-for-sale securities	5.1	-1.2
Changes in pension plans, net of taxes	0	0
Comprehensive income (loss)	-18.2	18
Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	-10.7	-9.4
Changes in foreign currency translation adjustment	-8.7	-1.3
Changes in unrealized holding gain on available-for-sale securities	0	0
Changes in pension plans, net of taxes	0.1	-0.6
Comprehensive income (loss)	($19.30)	($11.30)

Supplemental_Guarantor_Condens5

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Supplemental Condensed Consolidating Balance Sheet (Detail) (USD $)	Dec. 27, 2014	Sep. 27, 2014	Dec. 28, 2013	Sep. 28, 2013
In Millions, unless otherwise specified
Current assets:
Cash and cash equivalents	$544	$736.10	$442.50	$822.50
Restricted cash	5.1	5.5
Accounts receivable, net	400.5	396
Inventories	310.3	330.6
Deferred income tax assets	39	39.4
Prepaid income taxes	0	22.4
Prepaid expenses and other current assets	37.7	35.8
Intercompany receivables	0	0
Total current assets	1,336.60	1,565.80
Property, plant and equipment, net	458.2	461.9
Intangible assets, net	3,332.10	3,433.60
Goodwill	2,809.90	2,810.80
Other assets	141.3	142.6
Long term intercompany receivables	0	0
Investment in subsidiaries	0	0
Total assets	8,078.10	8,414.70
Current liabilities:
Current portion of long-term debt	139.4	114.5
Accounts payable	67	92.1
Accrued expenses	253	262.1
Deferred revenue	148.4	150.9
Intercompany payables	0	0
Total current liabilities	607.8	619.6
Long-term debt, net of current portion	3,815.40	4,153.20
Deferred income tax liabilities	1,345.70	1,375.40
Deferred service obligations – long-term	19.8	20.1
Long-term intercompany payables	0	0
Other long-term liabilities	187	183.4
Total stockholders’ equity	2,102.40	2,063
Total liabilities and stockholders’ equity	8,078.10	8,414.70
Eliminations
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	0	0
Prepaid income taxes	-3.1	-1.1
Prepaid expenses and other current assets	0	0
Intercompany receivables	-2,806.90	-2,720.20
Total current assets	-2,810	-2,721.30
Property, plant and equipment, net	0	0
Intangible assets, net	-10.6	-10.7
Goodwill	0	0
Other assets	0	0
Long term intercompany receivables	-13	-13
Investment in subsidiaries	-8,706.60	-8,747.70
Total assets	-11,540.20	-11,492.70
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	0	0
Accrued expenses	-3.1	-1.1
Deferred revenue	0	0
Intercompany payables	-2,807.10	-2,720.40
Total current liabilities	-2,810.20	-2,721.50
Long-term debt, net of current portion	0	0
Deferred income tax liabilities	0	0
Deferred service obligations – long-term	0	0
Long-term intercompany payables	-13	-13
Other long-term liabilities	0	0
Total stockholders’ equity	-8,717	-8,758.20
Total liabilities and stockholders’ equity	-11,540.20	-11,492.70
Parent/Issuer
Current assets:
Cash and cash equivalents	150.6	288.1	105.4	321.5
Restricted cash	0	0
Accounts receivable, net	116.2	128.4
Inventories	88	88.6
Deferred income tax assets	26.3	26.2
Prepaid income taxes	0	20.3
Prepaid expenses and other current assets	18.5	16.2
Intercompany receivables	0	0
Total current assets	399.6	567.8
Property, plant and equipment, net	27.8	29.7
Intangible assets, net	23.6	25.1
Goodwill	327.8	282.4
Other assets	82.7	88.4
Long term intercompany receivables	0	0
Investment in subsidiaries	8,490	8,526
Total assets	9,351.50	9,519.40
Current liabilities:
Current portion of long-term debt	139.4	114.5
Accounts payable	26.9	34.8
Accrued expenses	156.3	139.4
Deferred revenue	111	113.5
Intercompany payables	2,763.90	2,676.20
Total current liabilities	3,197.50	3,078.40
Long-term debt, net of current portion	3,815.40	4,153.20
Deferred income tax liabilities	97.3	90.9
Deferred service obligations – long-term	8.6	8.3
Long-term intercompany payables	13	13
Other long-term liabilities	117.3	112.6
Total stockholders’ equity	2,102.40	2,063
Total liabilities and stockholders’ equity	9,351.50	9,519.40
Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	249.4	287.8	237	387.4
Restricted cash	0	0
Accounts receivable, net	198.2	182.5
Inventories	174.6	190.1
Deferred income tax assets	11.7	12.1
Prepaid income taxes	3.1	3.2
Prepaid expenses and other current assets	10	11
Intercompany receivables	2,787.90	2,702.10
Total current assets	3,434.90	3,388.80
Property, plant and equipment, net	337.7	337.1
Intangible assets, net	3,279	3,377.30
Goodwill	2,390.80	2,390.90
Other assets	57.3	52.7
Long term intercompany receivables	0	0
Investment in subsidiaries	216.6	221.7
Total assets	9,716.30	9,768.50
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	32.7	46.1
Accrued expenses	48.4	69.5
Deferred revenue	8.3	7.4
Intercompany payables	0	0
Total current liabilities	89.4	123
Long-term debt, net of current portion	0	0
Deferred income tax liabilities	1,244.40	1,279.10
Deferred service obligations – long-term	3.9	3.6
Long-term intercompany payables	0	0
Other long-term liabilities	33	34.3
Total stockholders’ equity	8,345.60	8,328.50
Total liabilities and stockholders’ equity	9,716.30	9,768.50
Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	144	160.2	100	113.5
Restricted cash	5.1	5.5
Accounts receivable, net	86.1	85.1
Inventories	47.7	51.9
Deferred income tax assets	1	1.1
Prepaid income taxes	0	0
Prepaid expenses and other current assets	9.2	8.6
Intercompany receivables	19	18.1
Total current assets	312.1	330.5
Property, plant and equipment, net	92.7	95.1
Intangible assets, net	40.1	41.9
Goodwill	91.3	137.5
Other assets	1.3	1.5
Long term intercompany receivables	13	13
Investment in subsidiaries	0	0
Total assets	550.5	619.5
Current liabilities:
Current portion of long-term debt	0	0
Accounts payable	7.4	11.2
Accrued expenses	51.4	54.3
Deferred revenue	29.1	30
Intercompany payables	43.2	44.2
Total current liabilities	131.1	139.7
Long-term debt, net of current portion	0	0
Deferred income tax liabilities	4	5.4
Deferred service obligations – long-term	7.3	8.2
Long-term intercompany payables	0	0
Other long-term liabilities	36.7	36.5
Total stockholders’ equity	371.4	429.7
Total liabilities and stockholders’ equity	$550.50	$619.50

Supplemental_Guarantor_Condens6

Supplemental Guarantor Condensed Consolidating Financials - Schedule of Consolidating Statement of Cash Flows (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 27, 2014	Dec. 28, 2013
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	$153.50	$149.30
INVESTING ACTIVITIES
Net proceeds from sale of business	0	2.4
Purchase of property and equipment	-10.8	-8.4
Increase in equipment under customer usage agreements	-10.3	-8
Net sales of insurance contracts	-6.4	13.8
Purchases of mutual funds	0	29.7
Sales of mutual funds	6.4	15.9
(Increase) decrease in other assets	-0.9	-0.4
Net cash used in investing activities	-22	-14.4
FINANCING ACTIVITIES
Repayment of long-term debt	-328.8	-521.3
Net proceeds from issuance of common stock pursuant to employee stock plans	15.2	12.9
Excess tax benefit related to equity awards	3	3
Payment of minimum tax withholdings on net share settlements of equity awards	-10.6	-9.1
Net cash used in financing activities	-321.2	-514.5
Effect of exchange rate changes on cash and cash equivalents	-2.4	-0.4
Net decrease in cash and cash equivalents	-192.1	-380
Cash and cash equivalents, beginning of period	736.1	822.5
Cash and cash equivalents, end of period	544	442.5
Eliminations
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	0	0
INVESTING ACTIVITIES
Net proceeds from sale of business		0
Purchase of property and equipment	0	0
Increase in equipment under customer usage agreements	0	0
Net sales of insurance contracts	0	0
Purchases of mutual funds		0
Sales of mutual funds	0	0
(Increase) decrease in other assets	0	0
Net cash used in investing activities	0	0
FINANCING ACTIVITIES
Repayment of long-term debt	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent/Issuer
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	186.9	301.6
INVESTING ACTIVITIES
Net proceeds from sale of business		0
Purchase of property and equipment	-2.4	-2.9
Increase in equipment under customer usage agreements	0	-0.4
Net sales of insurance contracts	-6.4	13.8
Purchases of mutual funds		29.7
Sales of mutual funds	6.4	15.9
(Increase) decrease in other assets	-0.8	0.1
Net cash used in investing activities	-3.2	-3.2
FINANCING ACTIVITIES
Repayment of long-term debt	-328.8	-521.3
Net proceeds from issuance of common stock pursuant to employee stock plans	15.2	12.9
Excess tax benefit related to equity awards	3	3
Payment of minimum tax withholdings on net share settlements of equity awards	-10.6	-9.1
Net cash used in financing activities	-321.2	-514.5
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	-137.5	-216.1
Cash and cash equivalents, beginning of period	288.1	321.5
Cash and cash equivalents, end of period	150.6	105.4
Guarantor Subsidiaries
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	-25.9	-142
INVESTING ACTIVITIES
Net proceeds from sale of business		0
Purchase of property and equipment	-5.6	-3.2
Increase in equipment under customer usage agreements	-6.5	-4.3
Net sales of insurance contracts	0	0
Purchases of mutual funds		0
Sales of mutual funds	0	0
(Increase) decrease in other assets	-0.1	-1
Net cash used in investing activities	-12.2	-8.5
FINANCING ACTIVITIES
Repayment of long-term debt	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	-0.3	0.1
Net decrease in cash and cash equivalents	-38.4	-150.4
Cash and cash equivalents, beginning of period	287.8	387.4
Cash and cash equivalents, end of period	249.4	237
Non-Guarantor Subsidiaries
OPERATING ACTIVITIES
Net cash provided by (used in) operating activities	-7.5	-10.3
INVESTING ACTIVITIES
Net proceeds from sale of business		2.4
Purchase of property and equipment	-2.8	-2.3
Increase in equipment under customer usage agreements	-3.8	-3.3
Net sales of insurance contracts	0	0
Purchases of mutual funds		0
Sales of mutual funds	0	0
(Increase) decrease in other assets	0	0.5
Net cash used in investing activities	-6.6	-2.7
FINANCING ACTIVITIES
Repayment of long-term debt	0	0
Net proceeds from issuance of common stock pursuant to employee stock plans	0	0
Excess tax benefit related to equity awards	0	0
Payment of minimum tax withholdings on net share settlements of equity awards	0	0
Net cash used in financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	-2.1	-0.5
Net decrease in cash and cash equivalents	-16.2	-13.5
Cash and cash equivalents, beginning of period	160.2	113.5
Cash and cash equivalents, end of period	$144	$100